Enrolments completed for HPTN077
30 August 2015
Enrolments completed! The CAPRISA Vulindlela HPTN 077 team has just finished enrolling participants into its HPTN 077 study, a Phase IIa Safety, Tolerability and Acceptability Study of an Investigational Injectable HIV Integrase Inhibitor, Cabotegravir, for PrEP in HIV Uninfected Men and Women.